OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
July 11, 2024 07:00 ET
|
OKYO Pharma LTD
Phase 2 randomized, placebo-controlled trial in neuropathic corneal pain (NCP) patients planned to begin in Q3, 2024OK-101 is believed to be the first IND clearance granted by FDA for a drug to begin...
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
RAMM Pharma Corp. Provides Update on Litigation
May 21, 2024 17:01 ET
|
RAMM Pharma Corp.
Not for Dissemination in the US or through US Newswire Services TORONTO, May 21, 2024 (GLOBE NEWSWIRE) -- RAMM Pharma Corp. (including its wholly owned subsidiaries, the “Company” or "RAMM") (CSE:...
YPrime Transforms Endocrinology and Autoimmune Trials through New Glucometer and eCOA Integrated Functionality
May 21, 2024 08:00 ET
|
Y-Prime, LLC
YPrime's new glucometer/eCOA functionality offers a patient-centric, intuitive, and connected experience to clinical trial participants.
ALT INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALT
May 09, 2024 14:52 ET
|
The Rosen Law Firm PA
NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of...
AB Science:
May 07, 2024 12:05 ET
|
AB Science
COMMUNIQUE DE PRESSE UNE NOUVELLE PUBLICATION DANS LA REVUE MÉDICALE MUSCLE & NERVE VALIDE L’UTILISATION DU DECLIN DU SCORE ALSFRS-R (ΔFS) POUR LE DESIGN DES ETUDES CLINIQUES ET LE CHOIX DE...
AB Science : A new publication in the medical journal Muscle & Nerve validates the use of the rate of decline of ALSFR-S score (ΔFS) for the design of clinical studies and the treatment choice for amyotrophic lateral sclerosis (ALS) patient
May 07, 2024 12:05 ET
|
AB Science
PRESS RELEASE A NEW PUBLICATION IN THE MEDICAL JOURNAL MUSCLE & NERVE VALIDATES THE USE OF THE RATE OF DECLINE OF ALSFRS-R SCORE (ΔFS) FOR THE DESIGN OF CLINICAL STUDIES AND THE TREATMENT CHOICE...